PAUL LEE KORNBLITH
Medical Practice in Pittsburgh, PA
License number
Pennsylvania MD006939E
Category
Medicine
Type
Medical Physician and Surgeon
Address
Address
Pittsburgh, PA 15238
Personal information
See more information about PAUL LEE KORNBLITH at radaris.comName
Address
Phone
5015 Apple Ridge Dr, Allison Park, PA 15101
Pittsburgh, PA
907 Settlers Ridge Rd, Fox Chapel, PA 15238
5015 Apple Ridge Dr, Allison Park, PA 15101
Gibsonia, PA
Professional information
Method Of Using Multicellular Particulates To Analyze Malignant Or Hyperproliferative Tissue
US Patent:
6416967, Jul 9, 2002
Filed:
Nov 10, 1998
Appl. No.:
09/189310
Inventors:
Paul L. Kornblith - Pittsburgh PA
Assignee:
Precision Therapeutics, Inc. - Pittsburgh PA
International Classification:
C12Q 102
US Classification:
435 29, 435 30
Abstract:
A comprehensive and integrated system for monitoring (identifying, tracking and analyzing) an individual patients malignancy or hyperproliferative syndrome through the duration of a malignancy or hyperproliferative syndrome as to a specific patient is provided. Specimens of a patients cells are collected and mechanically separated into cohesive multicellular particulates. A tissue culture monolayer is grown from the multicellular particulates to form a prime culture, and the tissue culture is monitored over a period of time. The invention allows for study of the effect of various treatment methods on cellular production of vascular endothelial growth factor.
Method For Selecting Therapeutic Agents For Cancer Treatment
US Patent:
7678552, Mar 16, 2010
Filed:
Sep 10, 2008
Appl. No.:
12/208076
Inventors:
Paul L. Kornblith - Pittsburgh PA, US
Assignee:
Precision Therapeutics, Inc. - Pittsburgh PA
International Classification:
C12Q 1/24
US Classification:
435 30, 435 29, 435261
Abstract:
An improved system for screening a multiple of candidate therapeutic or chemotherapeutic agents for efficacy as to a specific patient, in which a tissue sample from the patient is harvested, cultured and separately exposed to a plurality of treatments and/or therapeutic agents for the purpose of objectively identifying. One particularly important tissue sample preparation technique is the initial preparation of cohesive multicellular particulates of the tissue sample. For assays concerning cancer treatment, a two-stage evaluation is contemplated in which both acute cytotoxic and longer term inhibitory effect of a given anti-cancer agent are investigated. The tissue sample technique of the present invention is also useful in assaying expression and/or secretion of various markers, factors or antigens present on or produced by the cultured cells for diagnostic purposes and for using such expression to monitor the applicability of certain candidate therapeutic or chemotherapeutic agents and the progress of treatment with those agents.
Method For Tandem Genomic/Proteomic Analysis Of Proliferating Cells
US Patent:
2004008, May 6, 2004
Filed:
Nov 17, 2003
Appl. No.:
10/399563
Inventors:
Paul Kornblith - Pittsburgh PA, US
Maryann Donovan-Peluso - Pittsburg PA, US
Maryann Donovan-Peluso - Pittsburg PA, US
International Classification:
C12Q001/68, C12Q001/66, G06F019/00, G01N033/48, G01N033/50
US Classification:
435/006000, 702/020000, 435/008000
Abstract:
A novel process for producing data characterizing nucleic acids in proliferating cells using a tandem protocol for simultaneously building and expanding genomics/proteomics cancer databases while coordinating present and future genomic/proteomic individual patient assays by collecting a tissue sample including the proliferating cells; mechanically dividing the sample into cohesive multicellular particulates, and growing and analyzing the resulting cells. Sets of genetic data can be analyzed along with sets of corresponding clinical data, including phenotypic data, to form profiles that can aid in identifying proliferative diseases and in prognoses. A method for diagnosing proliferative diseases using the described assay methods is also provided. Lastly, a computing device is provided which permits searching analysis and entry of the genetic data, the corresponding clinical data and/or profiles.
Method For Preparing Cell Cultures From Biological Specimens For Chemotherapeutic And Other Assays
US Patent:
6887680, May 3, 2005
Filed:
Jul 26, 2002
Appl. No.:
10/205887
Inventors:
Paul L. Kornblith - Pittsburgh PA, US
Assignee:
Precision Therapeutics, Inc. - Pittsburgh PA
International Classification:
C12Q001/02
US Classification:
435 29, 435 30, 435 32, 435261
Abstract:
An improved system for screening a multiple of candidate therapeutic or chemotherapeutic agents for efficacy as to a specific patient, in which a tissue sample from the patient is harvested, cultured and separately exposed to a plurality of treatments and/or therapeutic agents for the purpose of objectively identifying the best treatment or agent for the particular patient. Specific method innovations such as tissue sample preparation techniques render this method practically as well as theoretically useful. One particularly important tissue sample preparation technique is the initial preparation of cohesive multicellular particulates of the tissue sample, rather than enzymatically dissociated cell suspensions or preparations, for initial tissue culture monolayer preparation. With respect to the culturing of malignant cells, for example, it is believed (without any intention of being bound by the theory) that by maintaining the malignant cells within a multicellular particulate of the originating tissue, growth of the malignant cells themselves is facilitated versus the overgrowth of fibroblasts or other cells which tends to occur when suspended tumor cells are grown in culture. Practical monolayers of cells may thus be formed to enable meaningful screening of a plurality of treatments and/or agents.
Method For Preparing Cell Cultures From Biological Specimens For Chemotherapeutic And Other Assays
US Patent:
6900027, May 31, 2005
Filed:
Mar 17, 1998
Appl. No.:
09/040161
Inventors:
Paul L. Kornblith - Pittsburgh PA, US
Assignee:
Precision Therapeutics, Inc. - Pittsburgh PA
International Classification:
C12Q001/02
US Classification:
435 29, 435 30, 435 32, 435261
Abstract:
An improved system for screening a multiple of candidate therapeutic or chemotherapeutic agents for efficacy as to a specific patient, in which a tissue sample from the patient is harvested, cultured and separately exposed to a plurality of treatments and/or therapeutic agents for the purpose of objectively identifying the best treatment or agent for the particular patient. The system includes the initial preparation of cohesive multicellular particulates of the tissue sample, rather than enzymatically dissociated cell suspensions or preparations, for initial tissue culture monolayer preparation. Practical monolayers of cells may thus be formed to enable meaningful screening of a plurality of treatments and/or agents. By subjecting uniform samples of cells to a wide variety of active agents (and concentrations thereof), the most promising agent and concentration for treatment of a particular patient can be determined. For assays concerning cancer treatment, a two-stage evaluation is contemplated in which both acute cytotoxic and longer term inhibitory effect of a given anti-cancer agent are investigated.
Method For Preparing Cell Cultures From Biological Specimens For Chemotherapeutic And Other Assays
US Patent:
2004002, Feb 5, 2004
Filed:
Jul 30, 2002
Appl. No.:
10/208480
Inventors:
Paul Kornblith - Pittsburgh PA, US
Sheri Gimigliano - Pittsburgh PA, US
Sheri Gimigliano - Pittsburgh PA, US
Assignee:
Precision Therapeutics, Inc. - Pittsburgh PA
International Classification:
G01N033/574, C12N005/08
US Classification:
435/366000, 435/007230
Abstract:
An improved method for preparing a cell culture is disclosed. The method includes culturing a multicellular tissue explant in the presence of growth medium that is substantially free of enzymes capable of digesting the explant and, subsequently, removing the explant at a predetermined time.
Methods For Assessing Efficacy Of Chemotherapeutic Agents
US Patent:
2004007, Apr 15, 2004
Filed:
Jan 2, 2003
Appl. No.:
10/336659
Inventors:
Paul Kornblith - Pittsburgh PA, US
Sean McDonald - Pittsburgh PA, US
Sean McDonald - Pittsburgh PA, US
International Classification:
A61K031/00, C12Q001/68
US Classification:
514/001000, 435/006000
Abstract:
Methods are provided for accurately predicting efficacy of chemotherapeutic agents. Methods of the invention increase the positive predictive value of chemosensitivity assays by assessing both the ability of a chemotherapeutic to destroy cells and the genetic propensity of those cells for resistance. Results obtained using methods of the invention provide insight into the in vivo effectiveness of a therapeutic, and lead to more effective chemotherapeutic treatment.
Methods For Determining Efficacy Of Chemotherapeutic Agents
US Patent:
7771963, Aug 10, 2010
Filed:
Oct 2, 2008
Appl. No.:
12/244463
Inventors:
Paul L. Kornblith - Pittsburgh PA, US
Assignee:
Precision Therapeutics, Inc. - Pittsburgh PA
International Classification:
C12Q 1/24
US Classification:
435 30, 435 32, 435261
Abstract:
An improved system for screening a multiple of candidate therapeutic or chemotherapeutic agents for efficacy as to a specific patient, in which a tissue sample from the patient is harvested, cultured and separately exposed to a plurality of treatments and/or therapeutic agents for the purpose of objectively identifying the best treatment or agent for the particular patient. Specific method innovations such as tissue sample preparation techniques render this method practically as well as theoretically useful. By subjecting uniform samples of cells to a wide variety of active agents (and concentrations thereof), the most promising agent and concentration for treatment of a particular patient can be determined.
Methods For Assessing Efficacy Of Chemotherapeutic Agents
US Patent:
7829288, Nov 9, 2010
Filed:
Jul 28, 2009
Appl. No.:
12/510671
Inventors:
Paul L. Kornblith - Pittsburgh PA, US
Sean McDonald - Pittsburgh PA, US
Sean McDonald - Pittsburgh PA, US
Assignee:
Precision Therapeutics, Inc. - Pittsburgh PA
International Classification:
C12Q 1/68, C07H 21/02, C07H 21/04
US Classification:
435 6, 536 231, 536 243
Abstract:
Methods are provided for accurately predicting efficacy of chemotherapeutic agents. Methods of the invention increase the positive predictive value of chemosensitivity assays by assessing both the ability of a chemotherapeutic to destroy cells and the genetic propensity of those cells for resistance. Results obtained using methods of the invention provide insight into the in vivo effectiveness of a therapeutic, and lead to more effective chemotherapeutic treatment.
Methods For Determining Efficacy Of Chemotherapeutic Agents
US Patent:
2012008, Apr 12, 2012
Filed:
Oct 6, 2011
Appl. No.:
13/267581
Inventors:
Paul L. KORNBLITH - Pittsburgh PA, US
Assignee:
Precision Therapeutics, Inc. - Pittsburgh PA
International Classification:
C12Q 1/24
US Classification:
435 30
Abstract:
An improved system for screening a multiple of candidate therapeutic or chemotherapeutic agents for efficacy as to a specific patient, in which a tissue sample from the patient is harvested, cultured and separately exposed to a plurality of treatments and/or therapeutic agents for the purpose of objectively identifying the best treatment or agent for the particular patient. Specific method innovations such as tissue sample preparation techniques render this method practically as well as theoretically useful. By subjecting uniform samples of cells to a wide variety of active agents (and concentrations thereof), the most promising agent and concentration for treatment of a particular patient can be determined.